Organisation paid for research Program year 2024 Source: CMS Open Payments

Benchmark Research - Sacramento - HyperCore - PPDS

Neither a doctor nor a teaching hospital

Research payments

$13,364,367

2,496 payments

Through program year 2024, Benchmark Research - Sacramento - HyperCore - PPDS is reported as receiving $13,364,367 in research payments, across 2,496 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2024	Research	$6,736,173	540
2023	Research	$6,628,194	1,956

Breakdown

Who paid Research payments · program years 2023–2024

Moderna TX, Inc. $13,364,367 2,496 payments

Studies the money was for Research payments · program years 2023–2024

A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $2,846,929 888 payments
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $2,045,210 152 payments
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age $1,690,416 259 payments
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants $1,466,393 130 payments
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults $1,200,356 87 payments
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $812,101 40 payments
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine,mRNA-1195, in Healthy Adults 18 to 55 Years of Age $716,794 400 payments
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age $668,289 120 payments
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults $441,618 41 payments
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $339,472 28 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.